[Evolution of transcatheter aortic valve implantation from a high-volume Italian center: report of 2058 procedures over 15-year experience].

Evoluzione dell’impianto transcatetere di valvola aortica in un centro italiano ad alto volume: report di 2058 procedure in 15 anni di esperienza.

Journal

Giornale italiano di cardiologia (2006)
ISSN: 1972-6481
Titre abrégé: G Ital Cardiol (Rome)
Pays: Italy
ID NLM: 101263411

Informations de publication

Date de publication:
Jun 2022
Historique:
entrez: 8 6 2022
pubmed: 9 6 2022
medline: 10 6 2022
Statut: ppublish

Résumé

To assess the longitudinal changes in transcatheter aortic valve implantation (TAVI) practice and patients' outcomes in a high-volume Italian center. We analyzed all patients undergoing TAVI at our Institution from June 2007 to August 2021. We stratified the overall population considering four time periods according to procedural advancements and changes in clinical practice: period 1 (2007-2009, n=107) vs period 2 (2010-2014, n=449) vs period 3 (2015-2019, n=864) vs period 4 (2019-2021, n=638). Baseline and procedural characteristics, and in-hospital outcomes among the four groups were compared. A total of 2058 patients underwent TAVI receiving all the available devices. Patients had a median age of 82 years (78-85) with no differences among time periods. A stepwise reduction of median Society of Thoracic Surgeons mortality risk score (3.7 [2.8-5.3] vs 3.6 [2.6-5.4] vs 3.6 [2.5-5.5] vs 3.3 [2.2-4.9]; p=0.01) was observed. In-hospital all-cause-death (7.5% vs 5.1% vs 2.9% vs 3.0%; p<0.05), major stroke (4.7% vs 0.7% vs 1.0% vs 0.8%; p<0.05), major vascular complications (17.8% vs 8.7% vs 10.5% vs 5.8%; p<0.05) and permanent pacemaker implantation (23.4% vs 12.0% vs 8.7% vs 8.8%; p<0.05) rates significantly lowered over time. Device success markedly improved (80.4% vs 87.1% vs 95.0% vs 96.3%; p<0.05) with significant improvement of paravalvular regurgitation after TAVI (moderate-to-severe 16.8% vs 8.1% vs 0.7% vs 0.2%; mild 61.4% vs 38.2% vs 38.5% vs 25.6%; p<0.05). All-cause death and in-hospital outcomes of patients undergoing TAVI significantly improved accordingly to technical advancements and changes in clinical practice over 15-year experience.

Sections du résumé

BACKGROUND BACKGROUND
To assess the longitudinal changes in transcatheter aortic valve implantation (TAVI) practice and patients' outcomes in a high-volume Italian center.
METHODS METHODS
We analyzed all patients undergoing TAVI at our Institution from June 2007 to August 2021. We stratified the overall population considering four time periods according to procedural advancements and changes in clinical practice: period 1 (2007-2009, n=107) vs period 2 (2010-2014, n=449) vs period 3 (2015-2019, n=864) vs period 4 (2019-2021, n=638). Baseline and procedural characteristics, and in-hospital outcomes among the four groups were compared.
RESULTS RESULTS
A total of 2058 patients underwent TAVI receiving all the available devices. Patients had a median age of 82 years (78-85) with no differences among time periods. A stepwise reduction of median Society of Thoracic Surgeons mortality risk score (3.7 [2.8-5.3] vs 3.6 [2.6-5.4] vs 3.6 [2.5-5.5] vs 3.3 [2.2-4.9]; p=0.01) was observed. In-hospital all-cause-death (7.5% vs 5.1% vs 2.9% vs 3.0%; p<0.05), major stroke (4.7% vs 0.7% vs 1.0% vs 0.8%; p<0.05), major vascular complications (17.8% vs 8.7% vs 10.5% vs 5.8%; p<0.05) and permanent pacemaker implantation (23.4% vs 12.0% vs 8.7% vs 8.8%; p<0.05) rates significantly lowered over time. Device success markedly improved (80.4% vs 87.1% vs 95.0% vs 96.3%; p<0.05) with significant improvement of paravalvular regurgitation after TAVI (moderate-to-severe 16.8% vs 8.1% vs 0.7% vs 0.2%; mild 61.4% vs 38.2% vs 38.5% vs 25.6%; p<0.05).
CONCLUSIONS CONCLUSIONS
All-cause death and in-hospital outcomes of patients undergoing TAVI significantly improved accordingly to technical advancements and changes in clinical practice over 15-year experience.

Identifiants

pubmed: 35674037
doi: 10.1714/3810.37943
doi:

Types de publication

Journal Article

Langues

ita

Sous-ensembles de citation

IM

Pagination

461-468

Auteurs

Corrado Tamburino (C)

U.O.C. Cardiologia e UTIC.

Giuliano Costa (G)

U.O.C. Cardiologia e UTIC.

Valentina Frittitta (V)

U.O.C. Cardiologia e UTIC.

Roberto Valvo (R)

U.O.C. Cardiologia e UTIC.

Claudia Reddavid (C)

U.O.C. Cardiologia e UTIC.

Enrico Criscione (E)

U.O.C. Cardiologia e UTIC.

Orazio Strazzieri (O)

U.O.C. Cardiologia e UTIC.

Silvia Motta (S)

U.O.C. Cardiologia e UTIC.

Elena Di Pietro (E)

U.O.C. Cardiologia e UTIC.

Wanda Deste (W)

U.O.C. Cardiologia e UTIC.

Pierfrancesco Veroux (P)

U.O.C. Chirurgia Vascolare.

Valeria Garretto (V)

U.O.C. Radiologia.

Carmelo Sgroi (C)

U.O.C. Cardiologia e UTIC.

Carmelo Mignosa (C)

U.O.C. Cardiochirurgia, Centro di Alta Specialità e Trapianti, AOU Policlinico "G. Rodolico-San Marco", Catania.

Angelo Giuffrida (A)

U.O.C. Cardiochirurgia, Centro di Alta Specialità e Trapianti, AOU Policlinico "G. Rodolico-San Marco", Catania.

Marco Barbanti (M)

U.O.C. Cardiologia e UTIC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH